Skip to main content
Erschienen in: Clinical Pharmacokinetics 8/2014

01.08.2014 | Original Research Article

Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring

verfasst von: Manjunath P. Pai, Piergiorgio Cojutti, Federico Pea

Erschienen in: Clinical Pharmacokinetics | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Levofloxacin is a commonly prescribed antimicrobial where recommendations exist to reduce doses for renal impairment but not to increase doses for augmented renal function. Morbidly obese patients are increasing in prevalence, and represent a population that can have augmented renal function requiring higher-than-standard doses.

Objective

The current investigation was performed to characterize the pharmacokinetics (PK) and evaluate the influence of alternate body size descriptors and renal function as predictors of levofloxacin clearance (CL) and the area under the curve over 24 h (AUC24).

Methods

A database of patients undergoing levofloxacin therapeutic drug monitoring (TDM) were queried to identify patients ≥18 years of age with a body mass index ≥40 kg/m2. A maximum a posteriori probability Bayesian approach using a two-compartment linear PK model was used to estimate individual PK parameters and AUC24.

Results

A total of 394 concentration-time data points (peaks and trough) from 68 patients between 98 and 250 kg were evaluated. The median (5th, 95th percentile) daily dose and AUC24 was 1,000 (250, 1,500) mg and 90.7 (44.4, 228) mg·h/L, respectively. Levofloxacin CL was significantly (p < 0.05) related to height but not weight. As a result, levofloxacin CL was best related (R 2 = 0.57) to creatinine CL (CLcr) estimated by the Cockcroft–Gault (CG) equation and ideal body weight (IBW) because IBW is a height transformation. An empiric four-category daily-dose regimen (500, 750, 1,000, 1,250 mg) stratified by CLcr (CG-IBW) is expected to have >90 % probability of achieving an AUC24 of 50–150 mg·h/L in morbidly obese patients. Subsequent application of TDM and integration with pathogen-specific information could then be applied to tailor the levofloxacin regimen.

Conclusions

The proposed approach serves as a relevant alternative to the current fixed-dosing paradigm of levofloxacin in the morbidly obese.
Literatur
1.
Zurück zum Zitat Gallus S, Odone A, Lugo A, et al. Overweight and obesity prevalence and determinants in Italy: an update to 2010. Eur J Nutr. 2013;52(2):677–85.PubMedCrossRef Gallus S, Odone A, Lugo A, et al. Overweight and obesity prevalence and determinants in Italy: an update to 2010. Eur J Nutr. 2013;52(2):677–85.PubMedCrossRef
2.
Zurück zum Zitat van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14(1):9.PubMedCentralPubMedCrossRef van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14(1):9.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.PubMedCrossRef Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.PubMedCrossRef
4.
Zurück zum Zitat Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889–91.CrossRef Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond). 2013;37(6):889–91.CrossRef
5.
Zurück zum Zitat Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37(3):333–40.CrossRef Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37(3):333–40.CrossRef
6.
Zurück zum Zitat Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg. 2011;92(4):1420–6.PubMedCrossRef Zahr F, Genovese E, Mathier M, et al. Obese patients and mechanical circulatory support: weight loss, adverse events, and outcomes. Ann Thorac Surg. 2011;92(4):1420–6.PubMedCrossRef
7.
Zurück zum Zitat Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–6.PubMed Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–6.PubMed
8.
Zurück zum Zitat Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081–91.PubMedCrossRef Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081–91.PubMedCrossRef
9.
Zurück zum Zitat Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634–49.PubMedCrossRef Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634–49.PubMedCrossRef
10.
Zurück zum Zitat Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535–65.PubMedCrossRef Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68(4):535–65.PubMedCrossRef
11.
Zurück zum Zitat Michot JM, Seral C, Van Bambeke F, et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother. 2005;49(6):2429–37.PubMedCentralPubMedCrossRef Michot JM, Seral C, Van Bambeke F, et al. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother. 2005;49(6):2429–37.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127–67.PubMedCrossRef Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127–67.PubMedCrossRef
13.
Zurück zum Zitat Cook AM, Martin C, Adams VR, et al. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55(7):3240–3.PubMedCentralPubMedCrossRef Cook AM, Martin C, Adams VR, et al. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55(7):3240–3.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16.PubMedCrossRef Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16.PubMedCrossRef
15.
Zurück zum Zitat Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet. 2003;42(6):589–98.PubMedCrossRef Pea F, Di Qual E, Cusenza A, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet. 2003;42(6):589–98.PubMedCrossRef
16.
Zurück zum Zitat Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42(5):1098–104.PubMedCentralPubMed Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42(5):1098–104.PubMedCentralPubMed
17.
Zurück zum Zitat Drusano GL, Preston SL, Gotfried MH, et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2002;46(2):586–9.PubMedCentralPubMedCrossRef Drusano GL, Preston SL, Gotfried MH, et al. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2002;46(2):586–9.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Kashuba AD, Ballow CH, Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother. 1996;40(8):1860–5.PubMedCentralPubMed Kashuba AD, Ballow CH, Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother. 1996;40(8):1860–5.PubMedCentralPubMed
19.
Zurück zum Zitat Dumond JB, Nicol MR, Kendrick RN, et al. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012;51(12):809–22.PubMedCentralPubMedCrossRef Dumond JB, Nicol MR, Kendrick RN, et al. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012;51(12):809–22.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRef
21.
Zurück zum Zitat Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.PubMedCrossRef Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.PubMedCrossRef
22.
Zurück zum Zitat Devine B. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650–5. Devine B. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm. 1974;8:650–5.
23.
Zurück zum Zitat Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–7.PubMedCrossRef Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–7.PubMedCrossRef
24.
Zurück zum Zitat Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.PubMedCrossRef Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.PubMedCrossRef
25.
Zurück zum Zitat Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.PubMed Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.PubMed
26.
Zurück zum Zitat Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856–68.PubMedCrossRef Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32(9):856–68.PubMedCrossRef
28.
Zurück zum Zitat Zhang J, Xu JF, Liu YB, et al. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother. 2009;15(5):293–300.PubMedCrossRef Zhang J, Xu JF, Liu YB, et al. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother. 2009;15(5):293–300.PubMedCrossRef
29.
Zurück zum Zitat Alghanem S, Paterson I, Touw DJ, et al. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother. 2013;68(6):1338–47.PubMedCrossRef Alghanem S, Paterson I, Touw DJ, et al. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother. 2013;68(6):1338–47.PubMedCrossRef
30.
Zurück zum Zitat Emamian SA, Nielsen MB, Pedersen JF, et al. Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. AJR Am J Roentgenol. 1993;160(1):83–6.PubMedCrossRef Emamian SA, Nielsen MB, Pedersen JF, et al. Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. AJR Am J Roentgenol. 1993;160(1):83–6.PubMedCrossRef
31.
Zurück zum Zitat Akpinar IN, Altun E, Avcu S, et al. Sonographic measurement of kidney size in geriatric patients. J Clin Ultrasound 2003;31(6):315–8. Akpinar IN, Altun E, Avcu S, et al. Sonographic measurement of kidney size in geriatric patients. J Clin Ultrasound 2003;31(6):315–8.
32.
Zurück zum Zitat Glodny B, Unterholzner V, Taferner B, et al. Normal kidney size and its influencing factors: a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol. 2009;9:19.PubMedCentralPubMedCrossRef Glodny B, Unterholzner V, Taferner B, et al. Normal kidney size and its influencing factors: a 64-slice MDCT study of 1.040 asymptomatic patients. BMC Urol. 2009;9:19.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.PubMedCrossRef Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.PubMedCrossRef
34.
Zurück zum Zitat Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.PubMedCrossRef Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–8.PubMedCrossRef
35.
Zurück zum Zitat McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–30.PubMedCrossRef McLeay SC, Morrish GA, Kirkpatrick CM, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–30.PubMedCrossRef
36.
Zurück zum Zitat Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66(7):642–8.PubMedCrossRef Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66(7):642–8.PubMedCrossRef
37.
Zurück zum Zitat Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45(10):2793–7.PubMedCentralPubMedCrossRef Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2001;45(10):2793–7.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003;17(3):529–43.PubMedCrossRef Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 2003;17(3):529–43.PubMedCrossRef
39.
Zurück zum Zitat Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279(2):125–9.PubMedCrossRef Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279(2):125–9.PubMedCrossRef
40.
Zurück zum Zitat Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193–209.PubMedCrossRef Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193–209.PubMedCrossRef
41.
Zurück zum Zitat Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784–92.PubMedCrossRef Seeger JD, West WA, Fife D, et al. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784–92.PubMedCrossRef
42.
Zurück zum Zitat Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404–10.PubMedCrossRef Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404–10.PubMedCrossRef
43.
Zurück zum Zitat Kato M, Takada S, Ogawara S, et al. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995;39(9):1979–83.PubMedCentralPubMedCrossRef Kato M, Takada S, Ogawara S, et al. Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo. Antimicrob Agents Chemother. 1995;39(9):1979–83.PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Pham L, Christensen JM, Rodriguez-Proteau R. Pharmacokinetic prediction of levofloxacin accumulation in tissue and its association to tendinopathy. Pharmacol Pharm. 2013;4:121–31.CrossRef Pham L, Christensen JM, Rodriguez-Proteau R. Pharmacokinetic prediction of levofloxacin accumulation in tissue and its association to tendinopathy. Pharmacol Pharm. 2013;4:121–31.CrossRef
45.
Zurück zum Zitat Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance: what’s dosing got to do with it? Crit Care Med. 2008;36(8):2433–40.PubMedCrossRef Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance: what’s dosing got to do with it? Crit Care Med. 2008;36(8):2433–40.PubMedCrossRef
46.
Zurück zum Zitat Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8(1):5–12.PubMed Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8(1):5–12.PubMed
Metadaten
Titel
Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring
verfasst von
Manjunath P. Pai
Piergiorgio Cojutti
Federico Pea
Publikationsdatum
01.08.2014
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 8/2014
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0154-1

Weitere Artikel der Ausgabe 8/2014

Clinical Pharmacokinetics 8/2014 Zur Ausgabe